Junaxo is developing a portfolio of clinical development programs, initially with a focus on the treatment of amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Our current programs are based around compounds that are clinical trial ready and targets that have demonstrated proof-of-concept efficacy in the best pre-clinical models available.

Junaxo is a privately-held Canadian pharmaceutical development company investigating novel therapeutic compounds for the treatment of neurological disorders.

Junaxo was incorporated in 2013 and is located in Toronto.

Junaxo uses the ‘virtual’ model of drug development. By outsourcing its research requirements, Junaxo reduces its cash-burn enabling it to reach important scientific and financial milestones in a cost-effective way.

Core management experience is retained in-house enabling Junaxo to develop effective strategies and oversee outsourced research.


ABOUT Junaxo